- Patients
- Clinical Research
- Clinical trials
- Rag-01-01
Bladder Cancer
Rag-01-01
A phase I, single-arm, open label, multicenter, first-in-human trail to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of RAG-01 in patients with non-muscle invasive bladder cancer (NMIBC) who have failed Bacillus Calmette Guerin (BCG) therapy.
Trial overview
Medical Oncology
Bladder cancer
I
North Shore
North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia
(02) 8037 4100 admin.northshore@genesiscare.comMedical Oncologist
Dr Laurence Krieger
MBChB (Hons) FRACP
North Shore
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.